RaySearch Laboratories AB (publ) Interim Report January 1 – September 30, 2012

Read original

JANUARY 1 – SEPTEMBER 30, 2012

  • Net sales for the period amounted to SEK 105.2 M (80.3)

  • Loss after tax of SEK 5.5 M (profit: 10.2) was reported and loss per share was SEK 0.16 (earnings: 0.30)

  • Operating loss was SEK 3.7 M (profit: 13.0)

  • Cash flow amounted to SEK 14.8 M (deficit: 30.8)

  • The first complete version of RayStation® was released in January and an additional new version in August

  • A total of 14 orders for RayStation® were received from Australia, Italy, Canada, Switzerland, South Korea, Germany and the US

  • Distribution agreement signed for Spain in May

  • RaySearch licensed pioneering technology from Princess Margaret Hospital in September

AFTER THE END OF THE PERIOD

  • Record order for RayStation® from Austrian particle therapy center received in October
      

“The sharply increasing sales of RayStation® combined with continued strong sales of partner products led to a 31.0 percent revenue increase during the January to September period. However, earnings for the period were negative, due to higher costs for sales and marketing of RayStation® and high legal fees in the US,” says Johan Löf, President of RaySearch.

“During the first half of the year, we secured several key orders for RayStation® in North America, Europe and Asia and the positive trend continued after the end of the six-month period. Another major success was the order we received in October from the Austrian particle therapy center MedAustron for carbon ion treatment planning. The order is our largest to date and further strengthens our position in the particle therapy field,” concludes Johan Löf.
  

ABOUT RAYSEARCH
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with such leading partners as Philips, Nucletron, IBA Dosimetry, Varian, Accuray and Siemens. To date, 15 products have been launched through partners and RaySearch’s software is used at more than 2,000 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.

More information about RaySearch is available at www.raysearchlabs.com.
  

FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, President
Tel: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com

About Us

RaySearch Laboratories AB (publ) has been pushing the limits of advanced cancer treatment since 2000. Using progressive algorithms, RaySearch develops world leading software used by thousands of the most cutting-edge cancer clinics in the world. The algorithms are based upon founder and CEO Johan Löf’s scientific knowledge, acquired during his PhD on radiation treatment of moving tumors at the Karolinska Institute. The treatment planning system RayStation and the OIS RayCare are the result of extensive development during years of research, and today used to improve chances of survival and quality of life for cancer patients. We fight for a world where cancer is conquered.

Subscribe

Documents & Links